0000882104-21-000003.txt : 20210108 0000882104-21-000003.hdr.sgml : 20210108 20210108165339 ACCESSION NUMBER: 0000882104-21-000003 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210108 DATE AS OF CHANGE: 20210108 EFFECTIVENESS DATE: 20210108 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PDL BIOPHARMA, INC. CENTRAL INDEX KEY: 0000882104 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943023969 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-19756 FILM NUMBER: 21518120 BUSINESS ADDRESS: STREET 1: 59 DAMONTE RANCH PARKWAY STREET 2: SUITE B-375 CITY: RENO STATE: NV ZIP: 89521 BUSINESS PHONE: 775-832-8500 MAIL ADDRESS: STREET 1: 59 DAMONTE RANCH PARKWAY STREET 2: SUITE B-375 CITY: RENO STATE: NV ZIP: 89521 FORMER COMPANY: FORMER CONFORMED NAME: PROTEIN DESIGN LABS INC/DE DATE OF NAME CHANGE: 19930328 15-12G 1 a20210108form15.htm 15 Document

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number 000-19756

PDL BioPharma, Inc.
(Exact name of registrant as specified in its charter)

59 Damonte Ranch Parkway, Suite B-375
Reno, Nevada 89521
(775) 832-8500
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

Common Stock, par value $0.01 per share
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under Section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

Rule 12g-4(a)(1)☒
Rule 12g-4(a)(2)☐
Rule 12h-3(b)(1)(i)☒
Rule 12h-3(b)(1)(ii)☐
Rule 15d-6☐
Rule 15d-22(b)☐

Approximate number of holders of record as of the certification or notice date: Eighty-six (86).

Pursuant to the requirements of the Securities Exchange Act of 1934, PDL BioPharma, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

Date:January 8, 2021By:/s/ Dominique Monnet
Dominique Monnet
President and CEO